Active Wound Dressing

CYPATCH is a new paradigm in active wound dressings. The cell delivery coating technology has the potential to tackle a major challenge facing the woundcare industry – diabetic foot ulcers (DFU). In their chronic form, DFUs are a considerable burden on diabetic patients, where up to 25% of chronic wounds may become infected with considerable morbidity and mortality.

TekCyte’s CYPATCH is a proprietary surface-coating for wound dressings, optimised for the delivery of therapeutic adult stem cells directly to the wound bed, to accelerate wound repair.

This coating technology has been exclusively licensed to Cynata Therapeutics Limited (ASX: CYP).

CYPATCH - the cell delivery coating

Diabetes is the fastest growing chronic disease worldwide, affecting an estimated 425 million adults (1 in 11) globally in 2017 and forecasted to affect 629 million adults by 2045.

Up to 34% of those with diabetes will develop a foot ulcer, providing a portal for infection that can lead to life-threatening sepsis and/or amputation. With one diabetes-related extremity amputation now performed every 20 seconds, the burden on society associated with this condition is extremely.

Independent studies, utilising TekCyte’s coated dressing, were conducted by the Cooperative Research Centre for Cell Therapy Manufacturing (CTM-CRC), designed to compare Cynata’s Cymerus® cells with similar cells from various sources. The results showed that Cymerus cells were one of the most effective at accelerating wound repair in a small animal model.

Having secured a world-wide exclusive license from TekCyte, Cynata now plans to conduct a human clinical trial in patients with diabetic foot ulcers.

"The encouraging data from the pre-clinical studies provides a strong basis for us to proceed with our Cymerus MSC product utilising TekCyte’s patch technology as a potential treatment. We look forward to finalising trial design and start-up activities and to getting the clinical trial underway.”

How it works

TekCyte’s patented polymer coating for dressings was specifically designed to encourage the loose attachment of mesenchymal stem cells to the surface of the dressing. This loose attachment of the cells allows for their uniform release from the coated dressing, across the wound bed.

Apply active wound dressing

Evidence based results

Acute wounds in healthy and diabetic mice heal faster when treated with adult stem cells on CYPATCH. The quality of the healed wound, after 10 days, is superior to wounds that heal without stem cells.